Patent · US Active

Crystalline forms of a triazolopyrimidine compound

US11548897B2 · kind B2 · utility

0Cited by

6References

4Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Ying-Huey Huang · Taipei, TW
Bo Liu · San Diego, US
Liang Mao · Shanghai, CN
Long WANG · Shanghai, CN
Liladhar Murlidhar Waykole · East Hanover, US
Lijun Zhang · Los Altos Hills, US

Key dates

Filing date	Jul 9, 2021
Grant date	Jan 10, 2023
Priority date	—
Expiry date	Jul 14, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.